Executive Summary

BIOMEDICAL CLUSTER GROWTH
16.2%
YoY, first ten months of 2025
EDB Mfg 2025
NATIONAL R&D COMMITMENT
S$37bn
+32% over the prior plan
RIE2030 Plan
US TARIFF, PATENTED PHARMA
100%
Phased from 31 Jul 2026
US Sec 232 2026
SG-ORIGIN LICENCE-OUTS 2025
8deals
From three in 2022
Kira estimates

Capacity is the visible half

The biomedical manufacturing cluster grew 16.2% year on year across the first ten months of 2025, with the pharmaceuticals segment up 122.9% in October alone on higher active-ingredient and biological output [EDB Mfg 2025]. Against a base of S$38.1 bn in 2023 [EDB BMS 2023], we put 2025 output near S$43 bn and 2027 near S$49 bn [Kira estimates]. Disclosed additions alone bring 144,000 litres of drug-substance capacity on line between 2024 and 2027 [WuXi Bio 2026] [AbbVie 2024].

Origination is the harder half

The national drug-discovery platform has executed close to 20 licensing deals across 25 corporate partners and more than 70 academic institutions [EDDC AR 2025]. We count eight Singapore-origin out-licensing transactions in 2025 against three in 2022 [Kira estimates] — genuine momentum, set against US$135.7 bn of Chinese out-licensing value in the same year [China Lic 2026].

Biomedical manufacturing output
Singapore · S$ bn · 2023-2027F
S$ BN
SOURCE: MANUFACTURING PERFORMANCE RELEASES · KIRA TRIANGULATION · KIRA RESEARCH 2026
AbbVie 2024 = AbbVie Singapore biologics expansion announcement, Jan 2024 · China Lic 2026 = Chinese biopharma out-licensing deal-value tracker, 2025 full year and Q1 2026 · EDB BMS 2023 = EDB biomedical manufacturing output, 2023 · EDB Mfg 2025 = EDB monthly manufacturing performance releases, 2025 · EDDC AR 2025 = Experimental Drug Development Centre Annual Report 2025 · RIE2030 Plan = Research, Innovation and Enterprise 2030 plan · US Sec 232 2026 = US Executive Order on Section 232 pharmaceutical tariffs, Apr 2026 · WuXi Bio 2026 = WuXi Biologics Singapore CRDMO Hub disclosures · Kira estimates = KIRA in-house analyst triangulation

A narrow base, carrying a wide share of the economy

Biomedical output is concentrated in a handful of plants on one estate, yet it carries roughly a fifth of manufacturing value-added and the fifth-largest export line. Concentration cuts both ways — it delivers scale economics and it transmits any single policy shock straight through.

Weight out of proportion to footprint

Biomedical manufacturing generated S$38.1 bn of output in 2023 and supplied about 22% of total manufacturing value-added [EDB BMS 2023], on roughly 2.6% of gross domestic product [EDB BMS 2023]. Pharmaceutical products were the fifth-largest export line in 2024 at US$15.5 bn, ranking Singapore sixteenth among exporters worldwide [OEC Trade 2024].

The mix is tilting to biologics

We split the 2023 cluster at roughly S$27.0 bn pharmaceuticals and biologics against S$11.1 bn medical technology, moving to S$36.5 bn and S$12.5 bn by 2027 [Kira estimates]. The growth is disproportionately biologic: the October 2025 print showed the pharmaceuticals segment up 122.9% on higher active-ingredient and biological production [EDB Mfg 2025].

Commitment has not slowed

Investment commitments in 2025 reached S$14.2 bn of fixed assets, of which manufacturing took about S$12.1 bn, alongside S$8.9 bn of annual business spending and 15,700 jobs [EDB Review 2025]. Four companies joined the precision-medicine pre-competitive consortium in the same year [EDB Review 2025].

Cluster output by segment
Singapore · S$ bn · 2023 actual vs 2027 forecast
S$ BN
SOURCE: MANUFACTURING OUTPUT STATISTICS · KIRA SEGMENT SPLIT · KIRA RESEARCH 2026
EDB BMS 2023 = EDB biomedical manufacturing output and value-added share, 2023 · EDB Mfg 2025 = EDB monthly manufacturing performance releases, 2025 · EDB Review 2025 = EDB year in review, investment commitments 2025 · OEC Trade 2024 = Observatory of Economic Complexity, Singapore pharmaceutical product exports, 2024 · Kira estimates = KIRA in-house analyst triangulation